Company Filing History:
2 out of 78 
2 out of 228 
1 out of 832,880 Years Active: 2014-2021
Title: Adnan Fevzi Halim: Innovator in Glycoprotein Production
Introduction
Adnan Fevzi Halim is a notable inventor based in Malmö, Sweden. He has made significant contributions to the field of glycoprotein production, holding three patents that enhance the understanding and application of posttranslational modifications in proteins. His work is particularly relevant in the pharmaceutical industry, where these innovations can improve drug efficacy and safety.
Latest Patents
Halim's latest patents include groundbreaking inventions related to the production of N-glycoproteins. One of his patents focuses on a cell that expresses a polypeptide of interest with specific posttranslational modification patterns. These modifications are crucial for enhancing pharmacokinetic properties, such as the attachment of PEG chains to proteins. Another patent addresses N-glycosylation, detailing a mammalian cell that produces glycoproteins with modifications that enhance antibody-dependent cell-mediated cytotoxicity (ADCC). These inventions not only advance scientific knowledge but also have practical applications in therapeutic development.
Career Highlights
Throughout his career, Adnan Fevzi Halim has worked with prestigious institutions, including the University of Copenhagen and Danmarks Tekniske Universitet. His experience in these research environments has allowed him to develop and refine his innovative ideas, contributing to the advancement of biotechnological applications.
Collaborations
Halim has collaborated with esteemed colleagues such as Henrik Clausen and Zhang Yang. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and expertise, further enhancing the impact of his work.
Conclusion
Adnan Fevzi Halim is a prominent figure in the field of glycoprotein production, with a focus on posttranslational modifications that have significant implications for drug development. His patents and collaborations reflect a commitment to innovation and excellence in biotechnology.